A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL Meeting Abstract
| Authors: | Seiwert, T. Y.; Weiss, J.; Baxi, S. S.; Ahn, M. J.; Fayette, J.; Gillison, M. L.; Machiels, J. P. H.; Takahashi, S.; Melillo, G.; Franks, A.; Emeribe, U.; Raben, D.; McDevitt, M.; Psyrri, A. |
| Abstract Title: | A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 341s |
| Language: | English |
| ACCESSION: | WOS:000404711502227 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.TPS6101 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS6101 -- Source: Wos |
